CBDMD INC. DL-,001

cbdMD will publish results for the quarter ended 30 June 2026 on 13 August 2026. One analyst expects EPS of -0.030 USD per share versus -0.210 USD a year earlier and revenue of 5.7 mln USD (prior year 4.6 mln USD). For the current fiscal year the same analyst forecasts a loss of -0.190 USD per share with revenue of 22.2 mln USD (prior year 19.2 mln USD). » More on finanzen.net

At the annual meeting on March 30, cbdMD shareholders voted to elect seven board members and to appoint Cherry Bekaert as auditor. They also approved the 2025 equity compensation plan providing for issuance of 891,316 common shares and an annual “evergreen” provision; CEO T. Ronan Kennedy received 445,000 restricted shares. Shareholders authorized the board to implement a reverse stock split within one year at a ratio of 1-for-2 up to 1-for-10, and approved broad issuance authorities including conversion- and credit-line-related share issuances. cbdMD also completed the acquisition of Bluebird Botanicals and agreed to acquire assets of Gaia Botanicals, for which 425,000 restricted common shares are to be issued. » More on de.investing.com

Following the acquisition of Bluebird Botanicals, cbdMD is combining the scientific and regulatory resources of both companies and launching an integrated GRAS and regulatory-science program. The goal is to consolidate a safety and regulatory portfolio for broad‑spectrum and full‑spectrum cannabinoid formulations, prepare a self‑affirmed GRAS designation for broad‑spectrum products, and bolster Bluebird’s existing GRAS dossier. The acquisition is expected to increase revenue growth by roughly 10%; the stock has recently shown strong volatility, dropping nearly 10% over the past week. » More on de.investing.com